The tweet was deleted by the author.
But we saved everything 🙂.
Spyre Therapeutics announced its participation in three prominent industry conferences scheduled for September.
The company plans to connect with the investment community at Citi BioPharma Back to School, Wells Fargo Healthcare, and Stifel’s Immunology and Inflammation Forum. Webcasts from these conferences will be available for those interested in following the discussions and corporate updates. The events mark a strategic opportunity for Spyre Therapeutics to present its latest initiatives to investors and industry peers.
Details on the company's presentations and additional updates are expected to be released during the conference dates.
View post on X Loading...
Earlier this year, Spyre Therapeutics launched SPY772 and began a Phase 2 SKYLIGHT clinical trial to test a new approach for hidradenitis suppurativa, as detailed in company disclosures. The company is also developing SPY002, a novel monoclonal antibody targeting TL1A for inflammatory bowel disease, according to prior statements. These initiatives expand Spyre’s clinical portfolio heading into its September conference schedule.